One procedure that could relieve incontinence for years
In Houston and across four American cities, researchers are for the first time introducing a modified herpes virus into the human spinal cord — not to cause harm, but to carry a gene that may quietly restore what injury has taken away. The condition at the center of this effort, neurogenic bladder, ranks among the most urgent daily burdens for people living with spinal cord injuries, yet it has long been managed only through repeated, exhausting procedures. This trial asks whether a single intervention, working through the body's own nerve pathways, might offer something rarer than treatment: lasting relief. It is a moment where biotechnology and human dignity arrive at the same threshold together.
- Spinal cord injury patients face a relentless cycle of involuntary bladder contractions, incontinence, infections, and kidney damage — a crisis that patients themselves consistently name as their highest priority concern.
- Current botulinum toxin therapy demands up to 30 injections directly into the bladder every six months, a compounding burden that stretches across years of a patient's life.
- EG110A, a non-replicating herpes virus engineered to ferry botulinum toxin genes into spinal cord nerve cells, is now being tested in humans for the first time across four U.S. trial sites.
- A single spinal cord delivery could trigger continuous, localized toxin production that blocks involuntary nerve signals — with preclinical data suggesting the effect may last for years rather than months.
- The Phase Ib/IIa trial is proceeding with deliberate caution: 52 weeks of active monitoring, five years of safety follow-up, and FDA investigational clearance already secured, with the science now being asked to meet its promise.
At TIRR Memorial Hermann in Houston, physicians are preparing to inject a modified herpes virus into the spinal cords of people living with spinal cord injuries. The virus carries no disease and cannot replicate. What it carries instead is a gene designed to manufacture botulinum toxin precisely where it is needed — inside the nerve cells that govern bladder function. It is the first time this approach has ever been attempted in a human being.
The condition it targets, neurogenic bladder, emerges when spinal cord injury severs the nervous system's ability to coordinate bladder function. Without that coordination, bladder muscles contract without warning, producing constant urgency, frequent accidents, and a cascade of downstream harm: chronic urinary tract infections and, over time, irreversible kidney damage. When spinal cord injury patients are asked what matters most to them, bladder and bowel control rise consistently to the top.
Existing treatment already uses botulinum toxin, but delivers it through as many as 30 injections into the bladder muscle every six months — a procedure that must be repeated indefinitely. The new therapy, EG110A, developed by biotechnology company EG 427, takes a fundamentally different path. A single procedure deposits the gene therapy vector into the spinal cord, where the modified virus travels along nerve fibers to sensory cells and begins producing botulinum toxin continuously, blocking the signals that trigger involuntary contractions. Preclinical studies suggest the effect could endure for years.
Lead investigator Dr. Argyrios Stampas describes the approach as the kind of medicine he once only imagined — using a virus not as a threat but as a biological delivery system. For patients, the implications are profound: one intervention in place of a lifetime of repeated procedures.
The trial is structured with care. As a Phase Ib/IIa study, safety remains the primary focus. Participants are monitored for 52 weeks, with an additional five-year safety follow-up. The FDA has granted investigational new drug clearance, and the study is running across four sites — Houston, Los Angeles, Ann Arbor, and Philadelphia. What is at stake is not only whether the science holds, but whether it can return to people something that injury took: the quiet freedom of moving through the world without constant vigilance.
At TIRR Memorial Hermann in Houston, doctors are preparing to inject a modified herpes virus into the spinal cords of people living with spinal cord injuries. The virus carries no disease. It cannot multiply. What it does carry is a gene that will manufacture botulinum toxin directly where it's needed—in the nerve cells that control the bladder. This is the first time this approach has been tested in humans.
The problem the therapy aims to solve is neurogenic bladder, a condition that develops after spinal cord injury when the nervous system loses its ability to coordinate normal bladder function. The spinal cord normally orchestrates when the bladder fills and when it empties. After injury, that coordination breaks down. The bladder muscles contract involuntarily, without warning. People experience constant urgency, frequent accidents, and the cascade of complications that follow: repeated urinary tract infections, and over time, permanent damage to the kidneys themselves. When researchers ask spinal cord injury patients what matters most to them, bladder and bowel control consistently rank at the top.
Current treatment relies on botulinum toxin—the same substance used cosmetically—injected directly into the bladder muscle. The procedure requires as many as 30 injections every six months, a burden that compounds over years. The new therapy, called EG110A and developed by the biotechnology company EG 427, takes a fundamentally different approach. Instead of repeated injections into the bladder itself, a single procedure delivers the gene therapy vector directly into the spinal cord. The modified herpes virus, engineered to be harmless and unable to replicate, travels along nerve fibers to the sensory cells near the spinal cord. Once there, it begins producing botulinum toxin continuously, blocking the nerve signals that trigger involuntary contractions. Preclinical studies suggest the effect could last for years.
Dr. Argyrios Stampas, the lead investigator at the Houston site and an associate professor of physical medicine and rehabilitation at UTHealth Houston, describes the approach with evident wonder. This is the kind of therapy he imagined as an undergraduate—using the body's own biology as a delivery system, turning a virus into a tool rather than a threat. For patients, the potential shift is profound. Instead of managing a chronic condition with repeated procedures, they might undergo one intervention and experience years of relief.
The trial itself is cautious by design. It is a Phase Ib/IIa study, meaning it is still primarily focused on safety in this first human application. The trial will run for 52 weeks with an additional five-year safety follow-up period. Participants must be between 18 and 75 years old and at least 12 months past their spinal cord injury. Because this is a first-in-human study, an overnight hospital stay is required after the bladder injections. The FDA has already granted investigational new drug clearance, clearing the way to proceed. Houston is one of four sites across the country—the others are Rancho Los Amigos in Los Angeles, the University of Michigan in Ann Arbor, and Sidney Kimmel Medical College in Philadelphia. Visit-related expenses are covered for participants.
What makes this moment significant is not just the therapy itself but what it represents: a shift from managing symptoms to addressing the underlying nerve dysfunction. For people whose spinal cord injuries have already reshaped their lives, the prospect of a single procedure that could restore years of bladder control is not incremental progress. It is the kind of change that touches everything—dignity, independence, the ability to move through the world without constant vigilance. The trial will tell whether the science matches the promise.
Notable Quotes
This is the science fiction stuff that I dreamed about as an undergrad.— Dr. Argyrios Stampas, lead investigator at Houston site
When people living with spinal cord injury are surveyed, bowel and bladder issues are their top priority. The opportunity to have one procedure that could relieve incontinence for years would be a huge improvement on their quality of life.— Dr. Argyrios Stampas
The Hearth Conversation Another angle on the story
Why use a herpes virus at all? Why not just inject the gene therapy directly?
The herpes virus is a natural traveler along nerve fibers. It evolved to move through the nervous system. Scientists stripped away its ability to cause disease or replicate, but kept that navigation ability. It's using nature's own delivery system.
So the virus just sits there in the spinal cord, making botulinum toxin forever?
Not forever, but for years based on what they've seen in animals. That's the whole advantage—you're not chasing the problem with repeated injections. You solve it once and let the body do the work.
What happens if something goes wrong? If the gene keeps producing toxin and the patient can't empty their bladder?
That's exactly why there's a five-year safety follow-up. This is first-in-human. They're watching carefully. An overnight hospital stay after injection lets them monitor the immediate response. They're not rushing this.
For someone with a spinal cord injury, how much does bladder control actually matter?
It's their top priority. More than mobility, more than pain. Incontinence means constant UTIs, kidney damage, social isolation. It's not just inconvenience—it's a threat to long-term health and dignity.
Why hasn't something like this been tried before?
The technology didn't exist. Gene therapy vectors that are safe enough for human use, that can navigate the nervous system precisely—that's recent. This is what becomes possible when the underlying science matures.